Opportunities in the ER+/HER2- breast cancer market include the growth of novel CDK4/6 inhibitors and next-generation SERDs, offering advanced treatment options. Strong R&D from players like ...

The BRAF-mutated NSCLC market is poised for growth due to an increasing incidence rate across 7MM. Currently, only one approved therapy, the Tafinlar and Mekinist combo, targets this mutation.

Distribution of Immune Cells in Tumor Microenvironment Correlates With Checkpoint Inhibitor Response in Nasopharyngeal Carcinoma: A Multiregional Study We conducted a descriptive analysis of GLOBOCAN ...

Cost-Related Health Care Delays in Adolescents and Young Adults: Trends and Disparities From the 2009 to 2018 National Health Interview Survey Registered cases of cervical cancer aggregated over ...